CABA Cabaletta Bio, Inc.
Price Chart
Executive Summary
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 2026, including 83% (5/6) of dermatomyositis patients meeting the registrational primary endpoint, encouraging early PC-free lupus data showing deep B cell depletion in 1 of 2 patients, and plans to initiate a systemic sclerosis registrational study in 4Q26. The company also announced a 2H27 BLA submission target for myositis including adult and pediatric data, with potential for a priority review voucher.
Actionable Insight
The data strongly de-risks the myositis registrational program and adds a second pivotal indication in SSc, expanding the addressable market. The PC-free lupus data, while early, supports a potential market expansion thesis. Key catalysts to watch: SSc registrational study initiation in 4Q26, topline DM/ASyS registrational data in mid-2027, and PC-free dose-ranging data across indications. The favorable safety profile supporting outpatient administration could improve commercial adoption if approved.
Key Facts
- 83% (5/6) of Phase 1/2 dermatomyositis patients achieved IM-free moderate-to-major TIS response at 16 weeks, meeting the registrational primary endpoint threshold
- All 5 DM responders maintained IM-free response through latest follow-up as long as 1.5 years
- First JDM patient achieved IM-free moderate TIS response at 16 weeks, maintained at 32 weeks; JDM to be included in 2H27 BLA submission
- Systemic sclerosis announced as second pivotal indication; single-arm registrational study of ~25 patients with ILD expected to start in 4Q26
- Lowest dose of PC-free rese-cel achieved deep B cell depletion in 1 of 2 lupus patients; second patient had ~90% B cell reduction
- 94% of first 63 patients with preconditioning had no CRS or Grade 1 CRS only; 97% had no ICANS
- BLA submission for adult DM and JDM planned for 2H27, potentially qualifying for a priority review voucher
- SSc patients with ILD showed median 7.5% improvement in FVC at 36 weeks off immunomodulators
Financial Impact
No financial data provided in filing; company is pre-revenue clinical-stage biotech with $572M market cap
Risk Factors
- Phase 1/2 data may not predict registrational trial outcomes; ASyS durability was variable
- PC-free data is very early (2 lupus patients); higher dose cohorts still enrolling
- BLA submission in 2H27 is over a year away; regulatory pathway and approval are uncertain
- Company is pre-revenue with no approved products; will require additional capital to fund registrational trials and commercialization
- Competition from other CD19-CAR T programs in autoimmunity and approved therapies (IVIg, brepocitinib, Vyvgart)
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000030 |
| Document: caba-20260603.htm | 0001759138-26-000030 |
| Document: caba-ex99_1.htm | 0001759138-26-000030 |
| Document: 0001759138-26-000030-index-headers.html | 0001759138-26-000030 |
| Document: 0001759138-26-000030-index.html | 0001759138-26-000030 |
| Document: 0001759138-26-000030.txt | 0001759138-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $3.00 awaiting T+1 | awaiting T+1 | — | $3.01 (+0.33%) |
|
Jun 3, 2026
9d ago
|
8-K
| $3.58 $3.51 | ▼ −1.96% | ▼ −2.35% | $3.01 (−15.92%) |
|
Jun 1, 2026
11d ago
|
DEFA14A
| $3.67 $3.68 | ▲ +0.27% | ▲ +0.13% | $3.01 (−17.98%) |
|
May 14, 2026
29d ago
|
8-K
| $3.61 $3.31 | ▲ +8.31% | ▲ +7.08% | $3.01 (+16.62%) |
|
May 14, 2026
29d ago
|
Press Release
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.01 (−16.62%) |
|
May 14, 2026
29d ago
|
8-K
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.01 (−16.62%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.01 (+21.41%) |
|
May 4, 2026
5w ago
|
424B5
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.01 (+21.41%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▲ +8.36% | ▲ +7.56% | $3.01 (−21.41%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $2.86 $2.78 | ▼ −2.80% | ▼ −2.79% | $3.01 (+5.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access